The sequential use of a luteinizing hormone-releasing hormone (LH-RH) agonist and human menopausal gonadotropins to stimulate folliculogenesis in patients with resistant ovaries.
The diagnostic response toward the administration of a luteinizing hormone-releasing hormone (LH-RH) analogue in the early follicular phase has been used sequentially with conventional human menopausal gonadotropin (hMG) treatment in patients who had previously failed to develop multiple follicles in response to a combination of hMG and clomiphene citrate. Nine of fourteen patients (64%) showed an increase in the number of preovulatory follicles and five subjects reached oocyte recovery for the first time. Two patients (22%) became pregnant after in vitro fertilization and embryo transfer during the treatment cycle and had healthy babies. It is suggested that this treatment regimen may be advantageous in some patients with resistant ovaries.
D000328:Adult; D002064:Buserelin / Q000627:therapeutic use; D004338:Drug Combinations / Q000494:pharmacology*; D005260:Female; D005306:Fertilization / Q000187:drug effects; D005498:Follicular Phase / Q000187:drug effects*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D006801:Humans; D007247:Infertility, Female / Q000628:therapy; D008297:Male; D008596:Menotropins / Q000494:pharmacology*; D010053:Ovary / Q000503:physiopathology*; D010902:Pituitary Gland / Q000187:drug effects; D011247:Pregnancy
D004338:Drug Combinations; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D002064:Buserelin